| Pre-IPTW | Post-IPTW‡ | |||||
|---|---|---|---|---|---|---|
| Warfarin cohort (ref) | Apixaban cohort | STD† | Warfarin cohort (ref) | Apixaban cohort | STD† | |
| Sample size | 12,918 | 13,604 | 12,918 | 13,604 | ||
| Baseline comorbid conditions, n (%) | ||||||
| Bleeding history | 1951 (15) | 1678 (12) | 8.1 | 1767 (14) | 1866 (14) | 0.1 |
| Congestive heart failure | 4824 (37) | 4397 (32) | 10.6 | 4463 (35) | 4690 (34) | 0.2 |
| Diabetes mellitus | 7248 (56) | 6958 (51) | 10.0 | 6899 (53) | 7270 (53) | 0.1 |
| Hypertension | 11,193 (87) | 11,812 (87) | 0.5 | 11,206 (87) | 11,798 (87) | 0.1 |
| Renal disease | 1759 (14) | 2858 (21) | 19.6 | 2287 (18) | 2390 (18) | 0.4 |
| Liver disease | 524 (4) | 547 (4) | 0.2 | 519 (4) | 542 (4) | 0.2 |
| Myocardial infarction | 1845 (14) | 1862 (14) | 1.7 | 1802 (14) | 1888 (14) | 0.2 |
| Dyspepsia or stomach discomfort | 1421 (11) | 1319 (10) | 4.3 | 1317 (10) | 1395 (10) | 0.2 |
| Non-stroke/SE PVD | 2903 (22) | 2950 (22) | 1.9 | 2838 (22) | 2984 (22) | 0.1 |
| Stroke/SE | 1240 (10) | 1236 (9) | 1.8 | 1184 (9) | 1248 (9) | 0.0 |
| TIA | 786 (6) | 1258 (9) | 11.9 | 1009 (8) | 1051 (8) | 0.3 |
| Anemia and coagulation defects | 3157 (24) | 2875 (21) | 7.9 | 2918 (23) | 3070 (23) | 0.0 |
| Alcoholism | 4532 (35) | 5439 (40) | 10.1 | 4865 (38) | 5107 (38) | 0.3 |
| Peripheral artery disease | 2821 (22) | 2743 (20) | 4.1 | 2741 (21) | 2793 (21) | 1.7 |
| Coronary artery disease | 6814 (53) | 7288 (54) | 1.7 | 6729 (52) | 7365 (54) | 4.1 |
Please use landscape view or desktop screen to view the content.
Pre-IPTW and Post-IPTW Baseline Characteristics Among Obese* NVAF Patients Initiating Apixaban Versus Warfarin
Deitelzweig VA and Medicare 2022
